Profesionales

  • Noticias profesionales

Enrique Ruiz: “La carrera profesional tendrá un reconocimiento económico”

  • Noticias profesionales

SESCAM convoca 5.405 plazas para el concurso de traslados correspondiente a 2017

  • Noticias profesionales

Los médicos acuerdan iniciar movilizaciones durante el primer trimestre de 2018

  • Noticias profesionales

CESM rechaza que se obligue a los MIR a seguir un tiempo en la Sanidad pública

  • Noticias profesionales

Las pruebas de la OPE de Valencia para 19 especialidades comienzan el 13 de enero

  • Noticias profesionales

Los médicos piden aumentar las plantillas de los centros de salud

Ver más

Nuevo en Ginecología y Obstetricia

Combined obstetrics and sickle-cell clinic decreased mortality rate | ASH
  • Resúmenes de congresos
  • 1 comentario

Combined obstetrics and sickle-cell clinic decreased mortality rate | ASH

Program resulted in similar maternal and perinatal death rates between women with and without SCD.

Levothyroxine does not improve pregnancy outcomes for women with thyroid disease
  • Noticias Médicas Univadis
  • 1 comentario

Levothyroxine does not improve pregnancy outcomes for women with thyroid disease

Treatment with levothyroxine did not increase live-birth rates or reduce miscarriages.

  • Resúmenes Clínicos Univadis de Cancer
  • 1 comentario
  • TEXTO COMPLETO

Cáncer de ovario: las tasas de supervivencia en Estados Unidos continúan siendo al menos un 10 % inferiores en las mujeres de raza negra

Los datos del estudio CONCORD-2 muestran una modesta mejora en la supervivencia desde 2001-2003.

  • The ASCO Post
  • 1 comentario

SABCS 2017: Postmenopausal Women Who Lose Weight May Have Reduced Breast Cancer Risk

Postmenopausal women who lose weight may have a significantly reduced chance of developing breast cancer, according to new data presented by Chlebowski et al. Unlike earlier investigations of the association, this prospective study utilized a short-term, 3-year period of measured body weight and height followed by a long period of follow-up.

Anti-Müllerian hormone beneficial in diagnosing polycystic ovary syndrome
  • Noticias Médicas Univadis
  • 1 comentario

Anti-Müllerian hormone beneficial in diagnosing polycystic ovary syndrome

Anti-Müllerian hormone was more predictive of PCOS than either serum testosterone or free androgen index.

  • Resúmenes Clínicos Univadis de Oncotarget
  • 1 comentario
  • TEXTO COMPLETO

Un metanálisis relaciona el PVH y el cáncer de pulmón

Los datos muestran una asociación robusta para PVH 16 y 18.

  • The ASCO Post
  • 1 comentario

SABCS 2017: Older Women With Hormone Receptor–Positive Breast Cancer May Receive Similar Benefit From CDK4/6 Inhibitors as Younger Women

Older women with hormone receptor–positive, HER2-negative metastatic breast cancer who were treated with cyclin-dependent kinase 4/6 inhibitors achieved progression-free survival at a rate similar to that of younger women, according to data presented by Singh et al.

  • The ASCO Post
  • 1 comentario

SABCS 2017: SOLD Trial Data Support Current Standard 12-Month Adjuvant Trastuzumab for HER2-Positive Breast Cancer

Disease-free survival after 9 weeks of adjuvant trastuzumab and standard chemotherapy was not comparable to disease-free survival after 12 months of adjuvant trastuzumab and standard chemotherapy for women with early-stage HER2-positive breast cancer, supporting the current practice of extended trastuzumab treatment, according to data from the phase III Synergism or Long Duration (SOLD) clinical trial, presented by Joensuu et al.

  • The ASCO Post
  • 1 comentario

SABCS 2017: 2 Years of Extended Anastrozole Therapy Proved as Effective as 5 Years in Hormone Receptor–Positive Breast Cancer

Postmenopausal women with hormone receptor–positive breast cancer who took the aromatase inhibitor anastrozole for 2 years after an initial 5 years of adjuvant endocrine therapy received an equal benefit to those who took the drug for 5 additional years. The trial results suggest that a shorter duration of treatment may provide sufficient benefits while protecting women from harmful side effects, according to data from the ABCSG-16 trial presented by Gnant et al.

  • The ASCO Post
  • 1 comentario

SABCS 2017: Phase III EMBRACA Trial Meets Primary Endpoint

Patients with advanced HER2-negative breast cancer with germline <em>BRCA</em> mutations had significantly prolonged progression-free survival when treated with the poly(ADP-ribose) polymerase inhibitor talazoparib, compared with those who received chemotherapy of physician’s choice, according to data from the phase III EMBRACA trial presented by Litton et al.

  • The ASCO Post
  • sin comentarios

SABCS 2017: Circulating Tumor Cells May Predict Late Recurrence in Patients With Hormone Receptor–Positive Breast Cancer

Among patients with hormone receptor–positive HER2-negative stage II–III breast cancer without clinical evidence of recurrence, those who had circulating tumor cells detected in blood 5 years after diagnosis had an increased risk for late recurrence of breast cancer, according to data presented by Sparano et al.

Una vacuna experimental contra el Zika consigue una elevada respuesta inmunitaria en más del 90% de los pacientes (Lancet)
  • Noticias Médicas
  • 1 comentario

Una vacuna experimental contra el Zika consigue una elevada respuesta inmunitaria en más del 90% de los pacientes (Lancet)

Denominada ZPIV, contiene partículas inactivadas del virus, lo que impide que pueda replicarse y causar enfermedad en humanos.

  • Resúmenes Clínicos Univadis de N Engl J Med
  • 1 comentario

Los anticonceptivos hormonales aumentan el riesgo de cáncer de mama

A pesar de un mayor riesgo relativo, el aumento absoluto es de solo 1 caso adicional por cada 7690 usuarias.

  • Resúmenes Clínicos Univadis de Brachytherapy
  • 1 comentario

Carcinoma de endometrio en estadio II: ¿es la braquiterapia suficiente tratamiento complementario?

Sí, según un amplio estudio retrospectivo.